Yudai Tamura
Overview
Explore the profile of Yudai Tamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Tamura Y, Tamura Y, Tada Y
Cardiooncology
. 2024 Jul;
10(1):44.
PMID: 39020443
Background: Trastuzumab treatment for salivary gland, gastric, and breast cancer commonly causes cancer treatment-related cardiac dysfunction (CTRCD). CTRCD incidence by sex has not been well studied. Methods: This retrospective cohort...
3.
Tamura Y, Tamura Y, Shigeta A, Hosokawa K, Taniguchi Y, Inami T, et al.
Eur Respir J
. 2023 Dec;
62(6).
PMID: 38061784
Background: Peripheral pulmonary artery stenosis (PPS) refers to stenosis of the pulmonary artery from the trunk to the peripheral arteries. Although paediatric PPS is well described, the clinical characteristics of...
4.
Tamura Y, Lkhagvadorj S, Tamura Y, Furukawa A, Aida S, Ebinuma H, et al.
Front Cardiovasc Med
. 2023 Nov;
10:1295718.
PMID: 38028466
Background: This study investigates the pulmonary arterial histopathology in patients with idiopathic pulmonary arterial hypertension (IPAH) and acute vasoreactive phenotype, who demonstrated long-term survival (>30 years) and incidental death from...
5.
Tamura Y, Tamura Y
Pharmaceuticals (Basel)
. 2023 Sep;
16(9).
PMID: 37765105
Longitudinal strain (LS) measured by echocardiography has been reported to be useful not only for the diagnosis and risk stratification of various cardiac diseases, but also in cardio-oncology. Most previous...
6.
Atsukawa M, Tsubota A, Tamura Y, Koyano-Shioda K, Kawano T, Okubo T, et al.
JGH Open
. 2023 Aug;
7(8):588-590.
PMID: 37649860
The vertical and horizontal broken lines indicate the pre-revised criteria, whereas the vertical and horizontal solid lines indicate the 2022 European Society of Cardiology/European Respiratory Society criteria.
7.
Tamura Y, Takeyasu R, Takata T, Miyazaki N, Takemura R, Wada M, et al.
Pulm Circ
. 2023 Jun;
13(2):e12251.
PMID: 37342675
Pulmonary arterial hypertension (PAH), an intractable disease with a poor prognosis, is commonly treated using pulmonary vasodilators modulating the endothelin, cGMP, and prostacyclin pathway. Since the 2010s, drugs for treating...
8.
Tamura Y, Tamura Y, Taniguchi Y, Atsukawa M
Front Med (Lausanne)
. 2023 Apr;
10:1142836.
PMID: 37081835
Portopulmonary hypertension (PoPH) is a rare subtype of Group 1 pulmonary arterial hypertension (PAH) with a poor prognosis. According to the most up-to-date definition, PoPH is characterized by a mean...
9.
Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, et al.
JACC CardioOncol
. 2023 Jan;
4(5):673-685.
PMID: 36636435
Background: Immune checkpoint inhibitors (ICIs) are a central part of cancer therapy; however, cardiac complications, such as myocarditis, have the potential for significant morbidity and mortality. Within this population, the...
10.
Tamura Y, Tamura Y, Taniguchi Y, Tsujino I, Inami T, Matsubara H, et al.
Circ Rep
. 2022 Nov;
4(11):542-549.
PMID: 36408361
Portopulmonary hypertension (PoPH) is one of the major underlying causes of pulmonary arterial hypertension (PAH). However, PoPH, especially treatment strategies, has been poorly studied. Therefore, this study evaluated current treatments...